Novo Nordisk’s stock recently suffered its most significant drop since July 2002, attributed to heightened competition and underwhelming outcomes from various clinical trials. Nevertheless, analysts still hold optimistic views on the company’s shares, projecting a possible surge in value of up to 60% within the upcoming year.

Source: https://www.euronews.com/business/2025/04/01/novo-nordisk-shares-post-the-biggest-monthly-decline-since-2002